ABUS — Arbutus Biopharma Corp

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1447028 ·
Last close
$4.05
Market Cap
$620.84M
52W High
$5.45
52W Low
$3.50
ADV30
2,742,278
Next earnings
2026-11-10
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 1,014,000 — -5,751,000 -5,143,000 274,025,000 19,171,000 15,292,000
Mar 2026 179,126,000 — 169,117,000 169,695,000 277,164,000 23,706,000 16,987,000
Dec 2025 1,051,000 — -7,644,000 -3,756,000 94,618,000 18,008,000 18,042,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$221,004,000
Investing CF
$-319,000
Financing CF
$21,113,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$1.10
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,156,406,000
Inventory
—
Receivables
$792,000
ST Investments
$73,299,000
EBIT TTM
$219,975,000
Pretax Income TTM
$219,911,000
Interest Exp TTM
$64,000
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$181,490,000
EBITDA
$145,492,000
Free Cash Flow
$334,960,640
Enterprise Value
$292,786,656
Total Cash
$337,489,984
Total Debt
$3,309,000
Shares Out
153,292,826
Trailing EPS
$1.12
Book Value
$0.43
ROE
269.6%
ROA
41.6%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 14,083,000 -27,051,000 -33,501,000 94,618,000 18,042,000 76,576,000 -39,637,000
Dec 2024 6,171,000 -69,974,000 -69,920,000 131,707,000 34,341,000 97,366,000 -64,850,000
Dec 2023 18,141,000 -78,034,000 -72,849,000 144,401,000 38,383,000 106,018,000 -85,936,000
Dec 2022 39,019,000 -63,223,000 -69,456,000 195,419,000 58,567,000 136,852,000 -35,356,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$181,720,000
NetIncome TTM
$153,054,000
OpCashFlow TTM
—
Assets (Latest)
$274,025,000
Forward EPS
$-0.17

Max Pain — expiry 2027-01-15

max pain strike: $4.00 · spot: $4.11 · call oi: 2,323 · put oi: 547
Expected Move to 2027-01-15: ±$0.90 (21.90%) — implied range $3.21 – $5.01 · ATM straddle on $4.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ALMS ALUMIS INC. $628.33M $4.84 —
DSGN Design Therapeutics, Inc. $630.12M $9.84 —
OLMA Olema Oncology, Inc. $632.52M $7.22 —
BCAX Bicara Therapeutics Inc. $637.32M $9.60 —
IMMX Immix Biopharma, Inc. $603.45M $7.20 —

News headlines (Yahoo Finance, 1h cache)

Could Expanded Patent Lawsuits Change The Bull Case For BioNTech (BNTX)?
2026-11-13 10:14 · Yahoo
BioNTech (BNTX) Dropped, So What Is Driving Attention Now?
2026-11-13 09:11 · Yahoo
Arbutus: Q3 Earnings Snapshot
2026-11-10 12:36 · Yahoo
Arbutus Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-10 12:30 · Yahoo
Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor
2026-10-22 11:30 · Yahoo
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
2026-10-01 11:30 · Yahoo
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
2026-09-30 11:30 · Yahoo
Arbutus Biopharma shares jump after unveiling $230 million share buyback plan
2026-08-21 13:32 · Yahoo
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
2026-08-21 11:30 · Yahoo
Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?
2026-08-11 00:18 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.